Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Fridays weight loss is a telehealth provider that offers access to popular GLP-1 medications, including compounded versions ...

Hyderabad: Dr Reddy's Laboratories is positioning itself to enter the lucrative GLP-1 (glucagon-like peptide-1) drug market, ...

Research suggests a potential link between popular weight loss drugs and brain changes that may lead to depression, ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

Q1 2025 Earnings Call Transcript April 24, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported EPS ...